Iksuda Therapeutics reaches major milestone in cancer treatment development

Iksuda Therapeutics, a Newcastle Helix-based biotechnology company has reached a key step in the journey from laboratory research to patient care.

Iksuda Therapeutics has received clearance from the US Food and Drug Administration (FDA) to begin human clinical trials of IKS04, a new cancer treatment being developed for gastrointestinal cancers, including colorectal, gastric and pancreatic cancers.

The clearance follows approval of the company's Investigational New Drug (IND) application and means IKS04 can now move from pre-clinical development into a Phase 1 clinical trial in patients.

For any biotech company, this is a significant milestone. For Iksuda, it is also the third antibody-drug conjugate (ADC) in its pipeline to enter clinical development, following IKS014 and IKS03, both of which are already progressing through Phase 1 studies.

Commenting on the announcement, David Simpson, CEO of Iksuda Therapeutics, said:

"This IND clearance for IKS04 and the IKS04 Regimen is another important step for Iksuda and further validation of our approach to designing and developing innovative ADCs with the optimal clinical calibration for a given target and indication. IKS04 will be Iksuda's third ADC to enter clinical development, a significant milestone for the company, with IKS014 and IKS03 both currently progressing through Phase 1 studies. We look forward to progressing IKS04 into Phase 1 studies for GI cancers, an area of high unmet need with limited effective treatment options."

The milestone highlights the strength of the life sciences community at Newcastle Helix, where businesses, researchers and partners are working together to tackle major healthcare challenges through science, innovation and collaboration.

Congratulations to the Iksuda team on this significant achievement.

Read the full announcement on the Iksuda Therapeutics website